Articles scientifiques

Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer.

Auteurs : Dushyanthen S, Teo ZL, Caramia F, Savas P, Mintoff CP, Virassamy B, Henderson MA, Luen SJ, Mansour M, Kershaw MH, Trapani JA, Neeson PJ, Salgado R, McArthur GA, Balko JM, Beavis PA, Darcy PK, Loi S
Année : 2017
Journal : Nat Commun
Volume : 8
Pages : 606

DNA methylation-based immune response signature improves patient diagnosis in multiple cancers.

Auteurs : Jeschke J, Bizet M, Desmedt C, Calonne E, Dedeurwaerder S, Garaud S, Koch A, Larsimont D, Salgado R, Van den Eynden G, Willard-Gallo K, Bontempi G, Defrance M, Sotiriou C, Fuks F
Année : 2017
Journal : J Clin Invest
Volume : 127(8)
Pages : 3090-3102

Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: Current state of the art.

Auteurs : Solinas C, Carbognin L, De Silva P, Criscitiello C, Lambertini M
Année : 2017
Journal : Breast
Volume : 35
Pages : 142-150

CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer.

Auteurs : Gu-Trantien C, Migliori E, Buisseret L, de Wind A, Brohée S, Garaud S, Noël G, Dang Chi VL, Lodewyckx JN, Naveaux C, Duvillier H, Goriely S, Larsimont D, Willard-Gallo K
Année : 2017
Journal : JCI Insight
Volume : 2

Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.

Auteurs : Solinas C, Ceppi M, Lambertini M, Scartozzi M, Buisseret L, Garaud S, Fumagalli D, de Azambuja E, Salgado R, Sotiriou C, Willard-Gallo K, Ignatiadis M
Année : 2017
Journal : Cancer Treat Rev
Volume : 57
Pages : 8-15

Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer.

Auteurs : Buisseret L, Desmedt C, Garaud S, Fornili M, Wang X, Van den Eyden G, de Wind A, Duquenne S, Boisson A, Naveaux C, Rothé F, Rorive S, Decaestecker C, Larsimont D, Piccart-Gebhart M, Biganzoli E, Sotiriou C, Willard-Gallo K
Année : 2017
Journal : Mod Pathol
Volume : 30(9)
Pages : 1204-1212

The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast.

Auteurs : Pruneri G, Lazzeroni M, Bagnardi V, Tiburzio GB, Rotmensz N, DeCensi A, Guerrieri-Gonzaga A, Vingiani A, Curigliano G, Zurrida S, Bassi F, Salgado R, Van den Eynden G, Loi S, Denkert C, Bonanni B, Viale G
Année : 2017
Journal : Ann Oncol
Volume : 28
Pages : 321-328

Transcriptomic and genomic features of invasive lobular breast cancer.

Auteurs : Desmedt C, Zoppoli G, Sotiriou C, Salgado R
Année : 2017
Journal : Semin Cancer Biol
Volume : 44
Pages : 98-105

The immune infiltrate in prostate, bladder and testicular tumors: An old friend for new challenges.

Auteurs : Solinas C, Chanzá NM, Awada A, Scartozzi M
Année : 2017
Journal : Cancer Treat Rev
Volume : 53
Pages : 138-145

Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer.

Auteurs : Luen SJ, Savas P, Fox SB, Salgado R, Loi S
Année : 2017
Journal : Pathology
Volume : 49
Pages : 141-155

Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer.

Auteurs : Lambertini M, Del Mastro L, Viglietti G, Pondé NF, Solinas C, de Azambuja E
Année : 2017
Journal : Curr Treat Options Oncol
Volume : 18
Pages : 4

Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications.

Auteurs : Solinas C, Pusole G, Demurtas L, Puzzoni M, Mascia R, Morgan G, Giampieri R, Scartozzi M
Année : 2017
Journal : Crit Rev Oncol Hematol
Volume : 110
Pages : 106-116

FOXP1 is a key regulator of quiescence in healthy human CD3+ CD4+ T Cells and is constitutively repressed in CD3- CD4+ T cells from patients with lymphoproliferative disorders.

Auteurs : Garaud S, Roufosse F, De Silva P, Gu-Trantien C, Lodewyckx JN, Duvillier H, Dedeurwaerder S, Bizet M, Defrance M, Fuks F, Bex F, Willard-Gallo K
Année : 2017
Journal : Eur J Immunol
Volume : 47(1)
Pages : 168-179

Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.

Auteurs : Luen SJ, Salgado R, Fox S, Savas P, Eng-Wong J, Clark E, Kiermaier A, Swain SM, Baselga J, Michiels S, Loi S
Année : 2017
Journal : Lancet Oncol
Volume : 18(1)
Pages : 52-62

Adjuvant trastuzumab: a 10-year overview of its benefit.

Auteurs : Lambertini M, Pondé NF, Solinas C, de Azambuja E
Année : 2017
Journal : Expert Rev Anticancer Ther
Volume : 17
Pages : 61-74

RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.

Auteurs : Fumagalli D, Venet D, Ignatiadis M, Azim HA Jr, Maetens M, Rothé F, Salgado R, Bradbury I, Pusztai L, Harbeck N, Gomez H, Chang TW, Coccia-Portugal MA, Di Cosimo S, de Azambuja E, de la Peña L, Nuciforo P, Brase JC, Huober J, Baselga J, Piccart-Gebhart M, Loi S, Sotiriou C
Année : 2017
Journal : JAMA Oncol
Volume : 3
Pages : 227-234

Immunology of Solid Tumors Beyond Tumor-Infiltrating Lymphocytes: The Role of Tertiary Lymphoid Structures

Auteurs : Van den Eyden G, Salgado R, Willard-Gallo K
Année : 2017
Journal : Springer nature
Volume : -
Pages : 259-280

Targeting immune checkpoints in breast cancer: an update of early results.

Auteurs : Solinas C, Gombos A, Latifyan S, Piccart-Gebhart M, Kok M, Buisseret L
Année : 2017
Journal : ESMO Open
Volume : 2
Pages : e000255

Genomic Characterization of Primary Invasive Lobular Breast Cancer.

Auteurs : Desmedt C, Zoppoli G, Gundem G, Pruneri G, Larsimont D, Fornili M, Fumagalli D, Brown D, Rothé F, Vincent D, Kheddoumi N, Rouas G, Majjaj S, Brohée S, Van Loo P, Maisonneuve P, Salgado R, Van Brussel T, Lambrechts D, Bose R, Metzger O, Galant C, Bertucci F, Piccart-Gebhart M, Viale G, Biganzoli E, Campbell PJ, Sotiriou C
Année : 2016
Journal : J Clin Oncol
Volume : 34(16)
Pages : 1872-81

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.

Auteurs : Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, Vilgelm AE, Feld E, Johnson AS, Greenplate AR, Sanders ME, Lovly CM, Frederick DT, Kelley MC, Richmond A, Irish JM, Shyr Y, Sullivan RJ, Puzanov I, Sosman JA, Balko JM
Année : 2016
Journal : Nat Commun
Volume : 7
Pages : 10582